# US 2023/0058588 A1 · Circulating microrna as a marker for hepatocellular carcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058588 A1
- Document ID: US20230058588A1
- Status: Published application
- Kind: A1
- Application number: 17/892,804
- Filed: 2022-08-22
- Published: 2023-02-23
- Earliest claimed: 2010-03-12
- Assignees: Quest Diagnostics Investments Incorporated
- Applicants: Quest Diagnostics Investments LLC
- Inventors: Kevin Qu; Ke Zhang; Maher Albitar
- Web page: https://patentgrep.com/patent/US20230058588A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57525: of the liver or pancreas
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N 2333/471: Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods for the diagnosis, or management of liver diseases, e.g.. hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A method comprising:
(a) detecting a level of miR-199a miRNA in a serum sample from a human subject diagnosed as having hepatocellular carcinoma (HCC), wherein the serum sample is obtained from the subject prior to administration of an anti-cancer therapy, by:
(i) performing real-time reverse transcription polymerase chain reaction (RT-PCR) on the serum sample of (a) to measure a Ct value for miR-199a miRNA and a control Ct value for U6 small RNA, wherein the Ct value is measured using a detectably labeled probe specific for each miRNA assayed; and
(ii) calculating a delta Ct value by subtracting the U6 control Ct value from the miR-199a Ct value;
(b) detecting a level of miR-199a miRNA in a serum sample from the human subject diagnosed as having HCC, wherein the serum sample is obtained from the subject at a time point following to administration of the anti-cancer therapy, by:
(i) performing real-time reverse transcription polymerase chain reaction (RT-PCR) on the serum sample of (b) to measure a Ct value for miR-199a miRNA and a control Ct value for U6 small RNA, wherein the Ct value is measured using a detectably labeled probe specific for each miRNA assayed; and
(ii) calculating a delta Ct value by subtracting the U6 control Ct value from the miR-199a Ct value; and
(c) comparing the delta Ct value of (a)(ii) to the delta Ct value of (b)(ii).

### Claim 31 (depends on 30)

The method of claim 30, further comprising detecting the level of miR-16 miRNA in the serum sample of (a) and/or the serum sample of (b).

### Claim 32 (depends on 31)

The method claim 31, where the level of miR-16 miRNA in the serum sample of (a) and/or the serum sample of (b) is detected by (i) performing real-time reverse transcription polymerase chain reaction (RT-PCR) on the serum sample to measure a Ct value for miR-16 miRNA and a control Ct value for U6 small RNA, wherein the Ct value is measured using a detectably labeled probe specific for each miRNA assayed; and (ii) calculating a delta Ct value by subtracting the U6 control Ct value from the miR-16 Ct value.

### Claim 33 (depends on 30)

The method of claim 30, further comprising detecting at least one of the level of α-fetoprotein (AFP), the level of des-gamma-carboxyprothrombin (DCP), and the percentage of AFP-L3 in the serum sample of (a) and/or the serum sample of (b).

### Claim 34 (depends on 33)

The method of claim 33, wherein the level of α-fetoprotein (AFP) is detected by contacting the serum sample of (a) and/or the serum sample of (b) with an antibody that binds to AFP and detecting the binding between AFP and the antibody that binds to AFP.

### Claim 35 (depends on 34)

The method of claim 34, wherein the level of des-gamma-carboxyprothrombin (DCP) is detected by contacting the serum sample of (a) and/or the serum sample of (b) with an antibody that binds to DCP and detecting the binding between DCP and the antibody that binds to DCP.

### Claim 36 (depends on 34)

The method of claim 34, wherein the percentage of AFP-L3 in the serum sample is detected by contacting the serum sample of (a) and/or the serum sample of (b) with an antibody that binds to AFP-L3; and detecting the binding between AFP-L3 and the antibody that binds to AFP-L3.

### Claim 37 (depends on 30)

The method of claim 30, wherein the level of miR-199a, AFP, and DCP, and the percentage of AFP-L3 are detected in the serum sample of (a) and/or the serum sample of (b).

### Claim 38 (depends on 33)

The method of claim 33, wherein the level of AFP, the percentage AFP-L3, and the level of des-gamma-carboxyprothrombin (DCP) in the serum sample of (a) and/or the serum sample of (b) is greater than a reference value.

### Claim 39 (depends on 38)

The method of claim 38, wherein the reference value for AFP is 20 ng/mL.

### Claim 40 (depends on 38)

The method of claim 38, wherein the reference value for percentage AFP-L3 is 10%.

### Claim 41 (depends on 38)

The method of claim 38, wherein the reference value for DCP is 7.5 ng/ml.

### Claim 42 (depends on 30)

The method of claim 30, wherein the miR-199a delta Ct value in the serum sample of (a) is greater than 10.

### Claim 43 (depends on 31)

The method of claim 31, wherein the miR-16 delta Ct value in the serum sample of (a) is greater than 6.

### Claim 44 (depends on 30)

The method of claim 30, wherein anti-cancer therapy is chemotherapy, radiation therapy, and/or surgical resection.
